[Cyclosporin A in severe aplastic anemia in children]

Padiatr Padol. 1989;24(4):313-20.
[Article in German]

Abstract

Severe aplastic anemia should be treated with bone marrow transplantation if possible. Various clinical and experimental data support the view that the major pathogenetic defect in SAA is a dysregulated cellular immune response which in turn has a negative effect upon hematopoiesis. Therefore a large percentage of patients react favorably to treatment with immunosuppressive agents as antithymocyte globulin and high-dose methylprednisolone. Data concerning the efficiency of Cyclosporine A treatment are limited until now. We present in this report our own experience with Cyclosporine A treatment in three children with severe aplastic anemia who lack a bone marrow donor. Included is also a review of the present therapeutic possibilities.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Adolescent
  • Anemia, Aplastic / drug therapy*
  • Antilymphocyte Serum / administration & dosage
  • Cyclosporins / administration & dosage*
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Erythrocyte Count / drug effects
  • Female
  • Hemoglobinometry
  • Humans
  • Infant
  • Male
  • Methylprednisolone / administration & dosage
  • Pregnancy
  • Pregnancy Complications, Hematologic / drug therapy*
  • Reticulocytes / drug effects

Substances

  • Antilymphocyte Serum
  • Cyclosporins
  • Methylprednisolone